Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Sells $876,150.00 in Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha sold 55,000 shares of the company’s stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $15.93, for a total value of $876,150.00. Following the sale, the chief executive officer now directly owns 331,017 shares of the company’s stock, valued at $5,273,100.81. The trade was a 14.25 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Saurabh Saha also recently made the following trade(s):

• On Tuesday, January 21st, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $15.77, for a total value of $867,350.00.
• On Friday, December 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $17.44, for a total value of $959,200.00.
• On Friday, December 6th, Saurabh Saha sold 87,496 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $18.46, for a total value of $1,615,176.16.
• On Monday, November 25th, Saurabh Saha sold 299 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $18.23, for a total value of $5,450.77.
• On Friday, November 22nd, Saurabh Saha sold 1,671 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $18.24, for a total value of $30,479.04.

Centessa Pharmaceuticals Stock Performance

Shares of NASDAQ CNTA traded up $0.84 during trading hours on Thursday, reaching $16.75. The stock had a trading volume of 762,948 shares, compared to its average volume of 793,520. The business’s fifty day moving average is $16.71 and its two-hundred day moving average is $15.78. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. The company has a market cap of $2.21 billion, a price-to-earnings ratio of -10.95 and a beta of 1.53. Centessa Pharmaceuticals plc has a twelve month low of $7.75 and a twelve month high of $19.09.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Jane Street Group LLC acquired a new position in shares of Centessa Pharmaceuticals in the third quarter valued at $2,834,000. Wellington Management Group LLP acquired a new position in shares of Centessa Pharmaceuticals in the third quarter valued at $1,609,000. State Street Corp acquired a new position in shares of Centessa Pharmaceuticals in the third quarter valued at $777,000. Ally Bridge Group NY LLC acquired a new position in shares of Centessa Pharmaceuticals in the third quarter valued at $4,951,000. Finally, GSA Capital Partners LLP raised its stake in Centessa Pharmaceuticals by 66.1% during the third quarter. GSA Capital Partners LLP now owns 93,658 shares of the company’s stock worth $1,498,000 after acquiring an additional 37,275 shares in the last quarter. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently weighed in on CNTA. TD Cowen began coverage on Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They issued a “buy” rating for the company. Guggenheim reissued a “buy” rating on shares of Centessa Pharmaceuticals in a research report on Monday, February 10th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $25.83.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.